tirzepatide vs semaglutide safety weight loss effectiveness ✨ 𝐓𝐡𝐢𝐬 𝐖𝐞𝐞𝐤'𝐬 𝐌𝐮𝐬𝐭-𝐑𝐞𝐚𝐝 𝐢𝐧 𝐎𝐮𝐫 𝐍𝐞𝐰𝐬𝐥𝐞𝐭𝐭𝐞𝐫 ✨ We're breaking down one of the biggest conversations in medical weight loss right now: Tirzepatide vs Oral Semaglutide Tirzepatide vs Semaglutide UK: Mounjaro

You see visible particles, fibers, or floating material in the solution

Are GLP-1 microdosing strategies appropriate for everyone with extra weight

For people whose hair loss is driven by insulin resistance and metabolic dysfunction, tirzepatide may actually help rather than harm

BMJ 381 , e074572 (2023)

Chakravarthy is convinced it has a leg up on competitors because of its legacy in obesity research, its patient-centric approach, and its diagnostics expertise, which can help identify risk factors for obesity

Key Takeaways Retatrutide targets three hormones (GLP-1, GIP, glucagon), tirzepatide targets two (GLP-1, GIP), and semaglutide targets one (GLP-1) At 68 weeks, retatrutide achieved 28.7% average weight loss, tirzepatide approximately 22%, and semaglutide around 17% on the highest doses Side effects are similar across all three medications, mainly digestive issues like nausea and diarrhoea Retatrutide is not yet approved and won't be available until mid-2026 at the earliest Retatrutide is not yet approved and is not currently available in the UK Tirzepatide (Mounjaro) and semaglutide (Wegovy) are both available now in the UK through NHS or private providers By entering I agree to the Terms and Conditions